| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | de la Fuente Vivas, Dalia |
| dc.contributor.author | CAPPITELLI, VINCENZO |
| dc.contributor.author | García Gómez, Rocío |
| dc.contributor.author | Valero Díaz, Sara |
| dc.contributor.author | Amato, Camilla |
| dc.contributor.author | Rodriguez, Javier |
| dc.contributor.author | Duro Sánchez, Santiago |
| dc.contributor.author | Arribas, Joaquin |
| dc.date.accessioned | 2025-03-06T13:36:19Z |
| dc.date.available | 2025-03-06T13:36:19Z |
| dc.date.copyright | 2024 |
| dc.date.issued | 2025-02 |
| dc.identifier.citation | de la Fuente-Vivas D, Cappitelli V, García-Gómez R, Valero-Díaz S, Amato C, Rodriguéz J, et al. ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility. Mol Oncol. 2025 Feb;19(2):452-73. |
| dc.identifier.issn | 1878-0261 |
| dc.identifier.uri | http://hdl.handle.net/11351/12701 |
| dc.description | MAP kinases; Cell motility; Scaffold proteins |
| dc.description.abstract | ERK1/2 mitogen-activated protein kinases (ERK) are key regulators of basic cellular processes, including proliferation, survival, and migration. Upon phosphorylation, ERK becomes activated and a portion of it dimerizes. The importance of ERK activation in specific cellular events is generally well documented, but the role played by dimerization is largely unknown. Here, we demonstrate that impeding ERK dimerization precludes cellular movement by interfering with the molecular machinery that executes the rearrangements of the actin cytoskeleton. We also show that a constitutively dimeric ERK mutant can drive cell motility per se, demonstrating that ERK dimerization is both necessary and sufficient for inducing cellular migration. Importantly, we unveil that the scaffold protein kinase suppressor of Ras 1 (KSR1) is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, to unleash cellular motion. In agreement, clinical data disclose that high KSR1 expression levels correlate with greater metastatic potential and adverse evolution of mammary tumors. Overall, our results portray both ERK dimerization and KSR1 as essential factors for the regulation of cell motility and mammary tumor dissemination. |
| dc.language.iso | eng |
| dc.publisher | Wiley |
| dc.relation.ispartofseries | Molecular Oncology;19(2) |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Mama - Càncer - Aspectes genètics |
| dc.subject | Cèl·lules - Motilitat |
| dc.subject | Proteïnes quinases activades per mitògens |
| dc.subject.mesh | Breast Neoplasms |
| dc.subject.mesh | /genetics |
| dc.subject.mesh | Mitogen-Activated Protein Kinase 1 |
| dc.subject.mesh | Cell Movement |
| dc.title | ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1002/1878-0261.13732 |
| dc.subject.decs | neoplasias de la mama |
| dc.subject.decs | /genética |
| dc.subject.decs | proteína cinasa activada por mitógenos 1 |
| dc.subject.decs | movimiento celular |
| dc.relation.publishversion | https://doi.org/10.1002/1878-0261.13732 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [de la Fuente-Vivas D, Cappitelli V, Valero-Díaz S, Amato C] Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) – Universidad de Cantabria, Santander, Spain. [García-Gómez R] Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) – Universidad de Cantabria, Santander, Spain. Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. [Rodriguéz J] Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, UK. [Duro-Sánchez S, Arribas J] Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain. Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
| dc.identifier.pmid | 39263917 |
| dc.identifier.wos | 001310564500001 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |